We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion
Chief executive says revenue rise will allow drugmaker to boost investment in R&D
The latest strains have spread fast and governments are trying to catch up
New three-year contract in place if UK drugmaker continues to manufacture the jab
Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech
Doctors hopeful antibody therapy could change treatment for most common type of late-stage breast cancer
Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings
Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing
New therapies replace a blunderbuss with a stiletto
UK drugmaker’s R&D chief says abandoning market would have little impact
UK pharmaceuticals group raises dividend for first time in a decade
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors
Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’
Global health authorities have voiced concern that current jabs may afford less protection against variant
Protection against severe disease begins to wane three months after second shot
Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses
Chief executive says more data needed to explain Europe’s higher rate of admissions
Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge
British drugmaker’s exclusion from booster campaign is latest setback
Pharma group partnership with Oxford university hits 2bn-dose milestone
Pharma group to move away from non-profit model used during pandemic
Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year
Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare
International Edition
